EDBI Pte Ltd’s Keros Therapeutics KROS Stock Holding History

EDBI Pte Ltd’s Portfolio KROS Stock Details KROS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	$160K	Hold	10,105	–	–	0.17%	14
2024 Q3	$587K	Hold	10,105	–	–	0.79%	13
2024 Q2	$462K	Hold	10,105	–	–	0.52%	15
2024 Q1	$669K	Hold	10,105	–	–	0.75%	13
2023 Q4	$402K	Hold	10,105	–	–	0.4%	17
2023 Q3	$322K	Hold	10,105	–	–	0.35%	16
2023 Q2	$406K	Hold	10,105	–	–	0.33%	16
2023 Q1	$431K	Hold	10,105	–	–	0.48%	16
2022 Q4	$485K	Hold	10,105	–	–	0.62%	15
2022 Q3	$380K	Hold	10,105	–	–	0.4%	19
2022 Q2	$279K	Hold	10,105	–	–	0.26%	18
2022 Q1	$550K	Hold	10,105	–	–	0.37%	17
2021 Q4	$591K	Buy	+10,105	New	+$504K	0.32%	13

Other funds holding KROS

Fidelity Investments

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Holocene Advisors

Holocene Advisors New York $41.3B AUM 42.97% 1-Year Est. Return

Alkeon Capital Management

Alkeon Capital Management New York $22.1B AUM 51.63% 1-Year Est. Return

OrbiMed New York $4.59B AUM 125.28% 1-Year Est. Return

Nantahala Capital Management New Canaan, Connecticut $1.6B AUM 121.58% 1-Year Est. Return